9) notably,  #b1351 is markedly more resistant to neutralization by convalescent plasma (~11-33 fold) &amp; vaccinee sera (~6.5-8.6 fold). b.1.351 &amp; emergent variants with similar spike mutations present new challenges for mab therapy &amp; threaten the efficacy of current vaccines.